Brazil saved $US1 billion between 2001 and 2005 due to its government's policy of bargaining with pharma companies over the cost of antiretrovirals

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.542, 2007-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

For 2005, the cost to treat the ten most expensive health conditions in the US amounted to approximately $US500 billion

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 546, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Pharma companies offer drugs at low or no cost

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 395, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

China encourages price competition between pharma companies

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 284, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

US pharma industry fears government price controls

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 261, 2000-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

The US government's plans to end the pay-for-delay agreements between pharmaceutical and generic companies has been criticised

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 623, 2011-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite